Bioprinting: Markets and Opportunities

Bioprinting: Markets and Opportunities

SmarTech has been tracking the bioprinting industry for almost a decade and this is its third major bioprinting report. The report covers bioinks and bio-printing related applications, as well as well as the bioprinters themselves. Applications discussed in the report include drug discovery and testing, cosmetics testing, tissue and bone printing. We also examine the long-term prospects for transplanting bioprinted organs. And there is a chapter on new directions for bioprinting including discussions on soft robotics, pill printing, printed food.

The new SmarTech report provides a realistic assessment of bioprinting’s commercial future including analysis of what the major bioprinting companies are designing their marketing strategies. In addition to the pure play bioprinting companies, the bioprinting sector is seeing involvement from major life science companies and 3D printing companies. There are now well over 100 firms in the bioprinting sector, but most of these companies have negligible revenues. Among the firms that are discussed in this report are 3DBio Therapeutics, 3D Systems/Systemic Bio, BICO (Cellink), Collplant, Cyfuse, EnvisionTEC/Desktop Metal, FluidForm, Inventia Life Science, Organovo Holdings, Poietis, Regamat, Rokit Healthcare and many others.

According to Lawrence Gasman, Founder of SmarTech Analysis and author of the report, “New applications are quickly emerging for bioprinting, and they are very much in line with important megatrends in healthcare—notably the trends towards personalized medicine and bringing care closer to the patient. For example, bioprinting can enable procedures such as skin grafting to be performed in a clinic rather than at specialized hospitals.